Abstract:
Liquid biopsy has emerged as a minimally invasive technique for detecting and monitoring cancers through circulating biomarkers in blood and other body fluids. Unlike tissue biopsy, it offers a dynamic assessment of tumor burden, heterogeneity, and treatment response. This article reviews the principles, current applications, limitations, and future prospects of liquid biopsy in oncology.
Introduction:
Traditional cancer diagnosis relies on tissue biopsy, which is invasive, often limited by sampling error, and cannot capture tumor evolution over time.
Liquid biopsy analyzes tumor-derived material in fluids (blood, urine, CSF, pleural fluid), enabling real-time monitoring.
Rapid technological advancements (next-generation sequencing, digital PCR) have made it clinically feasible.
Key Components of Liquid Biopsy
1. Circulating Tumor Cells (CTCs)
Shed into blood from primary/metastatic tumors
Useful for prognosis and metastasis prediction
2. Circulating Tumor DNA (ctDNA)
Fragmented DNA released from apoptotic/necrotic tumor cells
Detects mutations (EGFR, KRAS, PIK3CA), microsatellite instability, and methylation changes
3. Cell-free RNA (cfRNA)
Includes mRNA, miRNA, lncRNA
Reflects gene expression and epigenetic regulation
4. Exosomes and Extracellular Vesicles
Nano-sized vesicles carrying DNA, RNA, proteins
Important for tumor–microenvironment communication
5. Tumor-educated Platelets (TEPs)
Platelets that uptake tumor RNA and proteins
Emerging biomarker source
Clinical applications :
1. Early Cancer Detection
Screening tool for lung, colorectal, breast, and pancreatic cancers
Multi-cancer early detection tests (MCED) under development
2. Diagnosis and Molecular Profiling
Identifies driver mutations for targeted therapy selection
Example: EGFR mutation detection in NSCLC using plasma ctDNA
3. Treatment Response Monitoring
Dynamic tracking of tumor burden
Detects resistance mutations (e.g., T790M in EGFR-mutated lung cancer)
4. Minimal Residual Disease (MRD) Detection
Identifies microscopic disease after surgery or chemotherapy
Predicts relapse earlier than imaging
5. Prognostication
High ctDNA levels correlate with poor survival in solid tumors
Advantages of liquid biopsy:
1. Minimally invasive and repeatable
2. Captures tumor heterogeneity better than a single-site biopsy
3. Provides real-time monitoring
4. Potentially useful in patients unfit for tissue biopsy
Limitations :
1. Sensitivity issues in early-stage cancers (low ctDNA levels)
2. Technical challenges: standardization, assay sensitivity, and specificity
3. High cost and limited availability in resource-limited settings
4. Interpretation requires integration with clinical and imaging data
Future directions:
1. Integration with artificial intelligence and machine learning for predictive modeling
2. Expansion of multi-omic approaches (DNA + RNA + protein + exosomes)
3. Development of point-of-care liquid biopsy tests
4. Personalized oncology through serial liquid biopsy monitoring
Conclusion:
Liquid biopsy represents a revolutionary tool in oncology, offering insights into cancer biology, real-time monitoring, and guiding precision medicine. While challenges remain in standardization and accessibility, ongoing research and clinical trials promise to make liquid biopsy a cornerstone of cancer diagnosis and management in the near future.